Hospira Recalls Marcaine Injection Vials Due to Sterility and Potency Defects
Hospira is recalling 4,768 vials of Marcaine 0.5% injection because a glass defect allowed water ingress, compromising sterility and reducing drug potency.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe rating under the rubric. The defect involves a loss of sterility assurance and subpotent drug, which are significant safety hazards for a perineural injection.
Plain-English summary
Hospira Inc., a Pfizer company, is recalling 4,768 vials of Marcaine (bupivacaine hydrochloride) 0.5% injection, USP. The affected product is the 250 mg/50 mL (5 mg/mL) multiple-dose vial, NDC 0409-1610-50, with lot number 59310DD and an expiration date of November 1, 2017. The recall covers distribution nationwide and in Puerto Rico.
The recall was initiated due to a defect in the glass vial that prevented the stopper from forming a proper seal. This defect allowed water to enter the vial, which diluted the product and resulted in a potency lower than labeled. Additionally, the breach in the seal compromised the assurance of sterility for the medication.
Healthcare providers and facilities that have received this specific lot of Marcaine should stop using the product and contact Hospira for instructions on return or disposal. Patients who have received this medication should consult their healthcare provider if they have concerns about their treatment.
The recalled product
- Product
- MARCAINE (BUPIVACAINE HYDROCHLORIDE)
- Brand
- MARCAINE
- Manufacturer
- Hospira Inc., A Pfizer Company
- Category
- Drug — Injection
- Hazard
- Affected units
- 4,768
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 59310DD
- Exp 1NOV2017
Distribution
Part of a larger recall action
This product is one of 2 recalled by Hospira Inc., A Pfizer Company under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · MARCAINE
- SevereHospira Recalls Marcaine Injection Due to Sterility and Potency Issues
FDA (Drugs) · 2016-10-19
- SevereHospira Recalls Marcaine Injection Vials Due to Visible Metal Particles
FDA (Drugs) · 2014-10-08
- CriticalHospira Recalls Marcaine Injection Vials Due to Visible Metal Particles
FDA (Drugs) · 2014-06-11
- SevereHospira Recalls Marcaine Injection Vials Due to Metal Particulate Matter
FDA (Drugs) · 2014-03-26
Same manufacturer · Hospira Inc., A Pfizer Company
See all →- ModerateHospira Recalls Labetalol Hydrochloride Injection Due to Cracked Glass Vials
FDA (Drugs) · 2018-03-14
- LowHospira Recalls Argatroban Injection Due to Impurity Specification Failure
FDA (Drugs) · 2017-07-26
- ModerateHospira Recalls Levophed Injection Due to Foreign Stopper Observation
FDA (Drugs) · 2017-06-21
- SevereHospira Recalls Vancomycin Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2017-04-12
- HighHospira Plum 360 Infusion Pump Software Recall for Battery Alarm Defect
FDA (Devices) · 2017-04-05
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29